특발성 아나필락시스 환자에서 오말리주맙의 치료 효과 = CASE REPORT : Favorable outcome of omalizumab treatment in a patient with idiopathic anaphylaxis

다국어 초록 (Multilingual Abstract)

Anaphylaxis is a severe and life-threatening systemic reaction. Despite the extensive evaluation to determine the cause, 30%-60% of cases of anaphylaxis in adults remain idiopathic. Recently, omalizumab treatment has been postulated to treat refractory idiopathic anaphylaxis. We report a case of idiopathic anaphylaxis treated with omalizumab and investigated its pharmacological mechanism. A 66-year-old female presented to our clinic with recurrent anaphylaxis. She suffered from anaphylaxis 2-3 times a month for 6 months. She had past medical history of nonallergic bronchial asthma. History was carefully undertaken and anaphylaxis was not related to any specific foods, drugs, exercise, and insect bites. Serum specific IgE antibodies to common food allergens showed negative results. Oral provocation tests to food additives revealed to be negative. To screen systemic mastocytosis and mast cell activating syndrome, baseline tryptase level was checked, and it was within normal range. From comprehensive evaluation, she was diagnosed as having idiopathic anaphylaxis. She could not tolerate oral medications due to gastrointestinal discomfort, therefore, omalizumab treatment (150 mg, monthly) was started. After 6 months of treatment, anaphylaxis did not occur with complete remission status. To evaluate the pharmacological mechanism of omalizumab treatment, basophil histamine releasability test was performed. Histamine releasability induced by anti-IgE did not change after 6 months of treatment, while that induced by calcium inophore decreased. Omalizumab treatment can induce remission or favorable effects on idiopathic anaphylaxis, which may be derived from increased threshold of mast cell degranulation. Long-term studies in a larger cohort will be needed to confirm its efficacy. (Allergy Asthma Respir Dis 2015;3:380-383)

참고문헌 (Reference)

1 Lieberman P, "The diagnosis and management of anaphylaxis practice parameter:2010 update" 126 : 477-480.e1-42, 2010

2 Zuberbier T, "The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update" 69 : 868-887, 2014

3 Demirturk M, "Promising option in the prevention of idiopathic anaphylaxis : omalizumab" 39 : 552-554, 2012

4 예영민, "Predictors of the Severity and Serious Outcomes of Anaphylaxis in Korean Adults: A Multicenter Retrospective Case Study" 대한천식알레르기학회 7 (7): 22-29, 2015

5 Wong S, "Outcome of prophylactic therapy for idiopathic anaphylaxis" 114 : 133-136, 1991

6 Gevaert P, "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma" 131 : 110-116.e1, 2013

7 Warrier P, "Omalizumab in idiopathic anaphylaxis" 102 : 257-258, 2009

8 Normansell R, "Omalizumab for asthma in adults and children" 1 : CD003559-, 2014

9 Jones JD, "Idiopathic anaphylaxis successfully treated with omalizumab" 101 : 550-551, 2008

10 Greenberger PA, "Idiopathic anaphylaxis" 27 : 273-293, 2007

11 Hur GY, "Histamine release and inflammatory cell infiltration in airway Mucosa in methylene diphenyl diisocyanate(MDI)-induced occupational asthma" 28 : 571-580, 2008

12 Chang TW, "Anti-IgE as a mast cell-stabilizing therapeutic agent" 117 : 1203-1212, 2006

13 Wood RA, "Anaphylaxis in America : the prevalence and characteristics of anaphylaxis in the United States" 133 : 461-467, 2014

14 김수정, "A Case of Idiopathic Anaphylaxis Followed by Acute Liver Injury" 대한천식알레르기학회 5 (5): 245-247, 2013